AC-480 had completed four clinical studies which are phase I study in patients with HER2-expressing advanced solid malignancies, phase I study in treating patients with metastatic solid tumor, phase I study in patients with advanced solid malignancies, including malignancies that express HER2 at the maximum tolerated dose and/or recommended, phase I dose and pharmacokinetic study of AC480 in patients with recurrent malignant glioma have all been completed [155,156,157,158] and safety study for intravenous (IV) AC-480 to treat advanced solid tumors has been withdrawn [159,160]. The gene discussed is ERBB2; the disease is malignant glioma.